Barclays
ORKA

Barclays’s Oruka Therapeutics ORKA Stock Holding History

Barclays’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.21M Sell
85,737
-87,592
-51% -$3.04M ﹤0.01% 1926
2025
Q4 		$5.25M Buy
173,329
+77,999
+82% +$2.17M ﹤0.01% 2179
2025
Q3 		$1.83M Buy
95,330
+4,166
+5% +$61.8K ﹤0.01% 2949
2025
Q2 		$1.02M Buy
91,164
+15,831
+21% +$165K ﹤0.01% 3326
2025
Q1 		$773K Buy
75,333
+750
+1% +$9.35K ﹤0.01% 3260
2024
Q4 		$1.45M Buy
+74,583
New +$1.82M ﹤0.01% 3129
2023
Q2 		– Sell
-4
Closed -$98 – 5161
2023
Q1 		$98 Buy
+4
New +$105 ﹤0.01% 4997
2018
Q2 		– Hold
0
– – – 7365
2018
Q1 		– Hold
0
– – – 7409

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return